PsyBio Therapeutics Corp
PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021. The company was incorporated… Read more
PsyBio Therapeutics Corp (PSYBF) - Total Assets
Latest total assets as of June 2023: $283.14K USD
Based on the latest financial reports, PsyBio Therapeutics Corp (PSYBF) holds total assets worth $283.14K USD as of June 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PsyBio Therapeutics Corp - Total Assets Trend (2016–2022)
This chart illustrates how PsyBio Therapeutics Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PsyBio Therapeutics Corp - Asset Composition Analysis
Current Asset Composition (December 2022)
PsyBio Therapeutics Corp's total assets of $283.14K consist of 64.9% current assets and 35.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2022)
This chart illustrates how PsyBio Therapeutics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PsyBio Therapeutics Corp's current assets represent 64.9% of total assets in 2022, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2022, down from 99.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
PsyBio Therapeutics Corp Competitors by Total Assets
Key competitors of PsyBio Therapeutics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
PsyBio Therapeutics Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PsyBio Therapeutics Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PsyBio Therapeutics Corp is currently not profitable relative to its asset base.
PsyBio Therapeutics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.89 | 4.73 |
| Quick Ratio | 0.05 | 0.89 | 4.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.86 Million | $ -129.08K | $ 124.11K |
PsyBio Therapeutics Corp - Advanced Valuation Insights
This section examines the relationship between PsyBio Therapeutics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 202.42 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -90.3% |
| Total Assets | $390.37K |
| Market Capitalization | $1.27K USD |
Valuation Analysis
Below Book Valuation: The market values PsyBio Therapeutics Corp's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: PsyBio Therapeutics Corp's assets decreased by 90.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PsyBio Therapeutics Corp (2016–2022)
The table below shows the annual total assets of PsyBio Therapeutics Corp from 2016 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $390.37K | -90.26% |
| 2021-12-31 | $4.01 Million | +1299.04% |
| 2020-12-31 | $286.50K | +77.33% |
| 2019-12-31 | $161.56K | -16.53% |
| 2018-12-31 | $193.55K | -6.09% |
| 2017-12-31 | $206.09K | -19.26% |
| 2016-12-31 | $255.24K | -- |